COVID-19 and Therapeutic Apheresis.
Horm Metab Res
; 54(8): 571-577, 2022 Aug.
Article
in English
| MEDLINE | ID: covidwho-1984481
ABSTRACT
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, is an unprecedented challenge for the global community. The pathogenesis of COVID-19, its complications and long term sequelae (so called Long/Post-COVID) include, in addition to the direct virus-induced tissues injury, multiple secondary processes, such as autoimmune response, impairment of microcirculation, and hyperinflammation. Similar pathological processes, but in the settings of neurological, cardiovascular, rheumatological, nephrological, and dermatological diseases can be successfully treated by powerful methods of Therapeutic Apheresis (TA). We describe here the rationale and the initial attempts of TA treatment in severe cases of acute COVID-19. We next review the evidence for the role of autoimmunity, microcirculatory changes and inflammation in pathogenesis of Long/Post COVID and the rationale for targeting those pathogenic processes by different methods of TA. Finally, we discuss the impact of COVID-19 pandemic on patients, who undergo regular TA treatments due to their underlying chronic conditions, with the specific focus on the patients with inherited lipid diseases being treated at the Dresden University Apheresis Center.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Blood Component Removal
/
COVID-19
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Horm Metab Res
Year:
2022
Document Type:
Article
Affiliation country:
A-1864-9482
Similar
MEDLINE
...
LILACS
LIS